IMGN ImmunoGen, Inc.

3.310.18 (+5.75%)
Close: September 20, 2019

Quote

Previous Close
$3.31
Day Range
$3.10-$3.35
52 Week Range
$1.76-$9.84
Volume
6,831,658
Avg Volume
1,659,679
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$496.12M
Enterprise Value (EV)
$384.16M
PE Ratio
-
EV/EBITDA
-2.56
Price/Sales
-
Price/Book
45.22
PEG Ratio
0.43

Financials

Revenue
-
Gross Profit
-
EBITDA
-$150.34M
EPS, ttm
-$1.18
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
11/1/2019 (40 days)
Debt to Equity
1,370%
Debt
$150.29M
Cash
$262.25M
Net Debt
-

Performance

Beta
1.61
200 Day Moving Avg
$3.27
50 Day Moving Avg
$2.68
52 Week Change
-63.47%
YTD Change
-25.00%
1 Month Change
21.69%
3 Month Change
68.88%
6 Month Change
28.79%
1 Year Change
-63.47%
2 Year Change
-12.23%
5 Year Change
-71.33%

Share Count

Shares Outstanding
149.9M
Float
147.7M
Restricted Shares
2.2M
Restricted Shares, %
1.49%

ImmunoGen, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Mark J. Enyedy

Website: http://www.immunogen.com

Description: ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.

Employees: 296